INO INOVIO PHARMACEUTICALS INC US FDA Inspections 8-K Filing 2023 - FDA Feedback on Clinical Trial Data INOVIO Pharmaceuticals has received feedback from the FDA that data from its Phase 1/2 clinical trial can be used to support the submission of a Biologic License Application (BLA) for its lead product candidate INO-3107.Get access to all SEC 8-K filings of the INOVIO PHARMACEUTICALS INC